Sofosbuvir + Ledipasvir

Janessa M. Smith, PharmD, BCPS

Sofosbuvir + Ledipasvir is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please log in or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

Monkeypox

Coronavirus COVID-19 (SARS-CoV-2)

Suicide Risk in the COVID-19 Pandemic

Moderna COVID-19 Vaccine

BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)

Managing Stress and Coping with COVID-19

Johnson & Johnson COVID-19 Vaccine

-- The first section of this topic is shown below --

INDICATIONS

FDA

Treatment of chronic hepatitis C virus (HCV) genotype 1, 4, 5 or 6 infection.
- Indicated for treatment of HCV infection in treatment-experienced patients without cirrhosis and with compensated cirrhosis (Child-Pugh A) or decompensated cirrhosis (Child-Pugh B or C)
- Treatment-naïve patients with compensated cirrhosis (Child-Pugh A) or decompensated cirrhosis (Child-Pugh B or C), and liver transplant recipients.

-- To view the remaining sections of this topic, please log in or purchase a subscription --

INDICATIONS

FDA

Treatment of chronic hepatitis C virus (HCV) genotype 1, 4, 5 or 6 infection.
- Indicated for treatment of HCV infection in treatment-experienced patients without cirrhosis and with compensated cirrhosis (Child-Pugh A) or decompensated cirrhosis (Child-Pugh B or C)
- Treatment-naïve patients with compensated cirrhosis (Child-Pugh A) or decompensated cirrhosis (Child-Pugh B or C), and liver transplant recipients.

There's more to see -- the rest of this topic is available only to subscribers.